Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) has a Wall Street consensus price target of $20.00, based on estimates from 21 covering analysts. With the stock currently trading at $8.23, this represents a potential upside of +143.0%. The company has a market capitalization of $224M.
Analyst price targets range from a low of $20.00 to a high of $20.00, representing a 0% spread in expectations. The median target of $20.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, ARCT trades at a trailing P/E of -2.7x. Analysts expect EPS to grow -12.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ARCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for ARCT is $20, representing 143.0% upside from the current price of $8.23. With 21 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ARCT has a consensus rating of "Buy" based on 21 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $20 implies 143.0% upside from current levels.
ARCT's current price is $8.23 with a consensus target of $20 (143.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $20 for ARCT, while the most conservative target is $20. The consensus of $20 represents the median expectation. These targets typically reflect 12-month expectations.
ARCT is well covered by analysts, with 21 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 7 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ARCT stock forecast based on 21 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $20 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ARCT, with a "Buy" consensus rating and $20 price target (143.0% upside). 10 of 21 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ARCT analyst price targets range from $20 to $20, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground.